FibroGen, Inc. (FGEN)
NASDAQ: FGEN · IEX Real-Time Price · USD
1.050
+0.010 (0.96%)
At close: Jul 19, 2024, 12:00 AM
1.060
+0.010 (0.95%)
Pre-market: Jul 22, 2024, 9:07 AM EDT
FibroGen Employees
FibroGen had 486 employees as of December 31, 2023. The number of employees decreased by 106 or -17.91% compared to the previous year.
Employees
486
Change (1Y)
-106
Growth (1Y)
-17.91%
Revenue / Employee
$344,636
Profits / Employee
-$494,774
Market Cap
104.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
InterCure | 270 |
Adicet Bio | 143 |
IO Biotech | 68 |
Cardiff Oncology | 32 |
Regulus Therapeutics | 30 |
Zentek | 24 |
Eledon Pharmaceuticals | 20 |
Coya Therapeutics | 8 |
FGEN News
- 6 weeks ago - FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials - GlobeNewsWire
- 6 weeks ago - FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors - GlobeNewsWire
- 2 months ago - FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology - GlobeNewsWire
- 2 months ago - FibroGen to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FibroGen Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - FibroGen to Report First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A - GlobeNewsWire
- 3 months ago - FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire